ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CCXI
- CUSIP: 16383L10
- Web: www.chemocentryx.com
Capitalization:- Market Cap: $405.62 million
- Outstanding Shares: 48,173,000
Average Prices:- 50 Day Moving Avg: $7.14
- 200 Day Moving Avg: $7.29
- 52 Week Range: $3.95 - $9.10
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.21
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $20.17 million
- Price / Sales: 20.97
- Book Value: $0.96 per share
- Price / Book: 9.15
Profitability:- EBIDTA: ($31,340,000.00)
- Return on Equity: -58.48%
- Return on Assets: -21.03%
Debt:- Current Ratio: 2.82%
- Quick Ratio: 2.82%
Misc:- Average Volume: 98,402 shs.
- Beta: 1.5
- Short Ratio: 26.55
Frequently Asked Questions for ChemoCentryx (NASDAQ:CCXI)
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.26) by $0.14. The company had revenue of $8.23 million for the quarter. View ChemoCentryx's Earnings History.
Where is ChemoCentryx's stock going? Where will ChemoCentryx's stock price be in 2017?
3 analysts have issued 12 month target prices for ChemoCentryx's stock. Their predictions range from $11.00 to $11.00. On average, they anticipate ChemoCentryx's share price to reach $11.00 in the next year. View Analyst Ratings for ChemoCentryx.
What are analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
- 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (3/20/2017)
- 2. Cowen and Company analysts commented, "ChemoCentryx reported a Q4:16 net loss of $8MM and a pro-forma cash balance of." (3/15/2017)
- 3. J P Morgan Chase & Co analysts commented, "ChemoCentryx announced a GAAP loss per share of $0.22. Overall, highlights on the call were incremental and the company continues to make steady progress across key programs. Of note, related to CCX168 in ANCA-associated vasculitis (AAV), the company has had initial discussions with US / EU regulatory bodies. Along with the recent strategic partnering with Vifor Pharma, we believe that the potential advancement of CCX168 into phase 3 would provide further validation to the phase 2 datasets (phase 3 program expected to start by YE16; see our thoughts from CLEAR and CLASSIC studies here and here). Looking forward beyond CCX168 in AAV, there are additional catalysts worth monitoring, including early data from CCX168 in aHUS (late-2016; potentially ASN in November) and ORR (3Q) / initial PFS (4Q) data for CCX872." (8/9/2016)
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Myovant Sciences Ltd (MYOV), Anika Therapeutics (ANIK), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), Syndax Pharmaceuticals (SNDX), Fortress Biotech (FBIO), Kamada (KMDA), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), VIVUS (VVUS), Cardiome Pharma Corporation (CRME), Strongbridge Biopharma plc (SBBP), Vericel Corporation (VCEL), Alimera Sciences (ALIM), KalVista Pharmaceuticals (KALV) and Tokai Pharmaceuticals (NVUS).
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Thomas J. Schall Ph.D., Chairman of the Board, President, Chief Executive Officer
- Susan M. Kanaya, Executive Vice President, Chief Financial and Administrative Officer, Secretary
- Petrus J. Bekker M.D., Ph.D., Senior Vice President - Clinical and Medical Affairs
- Israel F. Charo M.D., Ph.D., Senior Vice President - Research
- Markus J. Cappel Ph.D., Chief Business Officer, Treasurer
- Roger C. Lucas Ph.D., Lead Independent Director
- Henry A. McKinnell Jr., Ph.D., Director
- Thomas A. Edwards J.D., Independent Director
- Joseph M. Feczko M.D., Independent Director
- Geoffrey M. Parker, Independent Director
Who owns ChemoCentryx stock?
ChemoCentryx's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.49%), Acadian Asset Management LLC (1.77%), Renaissance Technologies LLC (1.28%), Iguana Healthcare Management LLC (0.52%), Oxford Asset Management (0.45%) and Geode Capital Management LLC (0.41%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya, Thomas A Edwards and Value Fund L P Biotechnology. View Institutional Ownership Trends for ChemoCentryx.
Who sold ChemoCentryx stock? Who is selling ChemoCentryx stock?
ChemoCentryx's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., City Financial Investment Co Ltd, Oxford Asset Management, Bank of America Corp DE, Bogle Investment Management L P DE, Banque Pictet & Cie SA, Iguana Healthcare Management LLC and Citadel Advisors LLC. Company insiders that have sold ChemoCentryx stock in the last year include Markus J Cappel, Petrus Bekker and Roger C Lucas. View Insider Buying and Selling for ChemoCentryx.
Who bought ChemoCentryx stock? Who is buying ChemoCentryx stock?
ChemoCentryx's stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Spark Investment Management LLC, EcoR1 Capital LLC, Thrivent Financial For Lutherans, Vanguard Group Inc., Eagle Global Advisors LLC and American Century Companies Inc.. Company insiders that have bought ChemoCentryx stock in the last two years include Geoffrey M Parker and Thomas A Edwards. View Insider Buying and Selling for ChemoCentryx.
How do I buy ChemoCentryx stock?
Shares of ChemoCentryx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of ChemoCentryx stock can currently be purchased for approximately $8.78.
MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ChemoCentryx (NASDAQ:CCXI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $11.00 (25.28% upside) |
Analysts' Ratings History for ChemoCentryx (NASDAQ:CCXI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/15/2017 | Cowen and Company | Reiterated Rating | Hold | | High |  |
| 2/21/2017 | JMP Securities | Initiated Coverage | Mkt Outperform -> Outperform | | N/A | |
| 8/9/2016 | J P Morgan Chase & Co | Reiterated Rating | Buy | $11.00 | N/A | |
(Data available from 6/27/2015 forward)
Earnings History for ChemoCentryx (NASDAQ:CCXI)Earnings History by Quarter for ChemoCentryx (NASDAQ CCXI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | ($0.26) | ($0.12) | | $8.23 million | View | N/A | |
| 3/14/2017 | Q4 2016 | ($0.22) | ($0.16) | | $4.89 million | View | N/A | |
| 11/7/2016 | Q3 | ($0.08) | ($0.15) | | | View | Listen | |
| 5/10/2016 | Q1 | ($0.27) | ($0.34) | | | View | Listen | |
| 3/14/2016 | Q4 | ($0.28) | ($0.26) | | | View | N/A | |
| 11/9/2015 | Q315 | ($0.29) | ($0.26) | | | View | Listen | |
| 8/6/2015 | Q215 | ($0.29) | ($0.28) | | | View | N/A | |
| 5/6/2015 | Q115 | ($0.28) | ($0.28) | | | View | Listen | |
| 3/12/2015 | Q414 | ($0.28) | ($0.28) | | | View | Listen | |
| 11/5/2014 | Q3 2014 | ($0.29) | ($0.25) | | | View | N/A | |
| 5/8/2014 | Q114 | ($0.24) | ($0.27) | $0.38 million | | View | N/A | |
| 3/13/2014 | | ($0.25) | ($0.22) | $1.37 million | $0.73 million | View | N/A | |
| 8/12/2013 | Q2 2013 | ($0.28) | ($0.23) | $1.48 million | $1.90 million | View | N/A | |
| 5/13/2013 | Q1 2013 | ($0.27) | ($0.28) | $2.04 million | $1.90 million | View | N/A | |
| 11/13/2012 | Q312 | | ($0.28) | $1.44 million | $1.13 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ChemoCentryx (NASDAQ:CCXI)Current Year EPS Consensus Estimate: $-0.72 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS
Dividend History for ChemoCentryx (NASDAQ:CCXI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ChemoCentryx (NASDAQ:CCXI)Insider Ownership Percentage: 26.80%
Institutional Ownership Percentage: 49.36%
Insider Trades by Quarter for ChemoCentryx (NASDAQ:CCXI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/1/2017 | Roger C Lucas | Director | Sell | 4,000 | $7.31 | $29,240.00 | |
| 1/3/2017 | Markus J Cappel | Insider | Sell | 26,821 | $7.51 | $201,425.71 | |
| 12/16/2016 | Petrus Bekker | Insider | Sell | 8,712 | $8.74 | $76,142.88 | |
| 12/5/2016 | Petrus Bekker | Insider | Sell | 30,000 | $8.50 | $255,000.00 | |
| 11/22/2016 | Petrus Bekker | Insider | Sell | 1,250 | $8.30 | $10,375.00 | |
| 11/11/2016 | Petrus Bekker | Insider | Sell | 33,332 | $8.00 | $266,656.00 | |
| 9/1/2016 | Roger C Lucas | Director | Sell | 4,000 | $5.07 | $20,280.00 | |
| 5/23/2016 | James L Tyree | Director | Sell | 5,544 | $4.39 | $24,338.16 | |
| 5/17/2016 | Thomas A Edwards | Director | Buy | 50,000 | $4.05 | $202,500.00 | |
| 5/16/2016 | Thomas A Edwards | Director | Buy | 25,000 | $4.05 | $101,250.00 | |
| 5/13/2016 | Geoffrey M Parker | Director | Buy | 40,000 | $4.03 | $161,200.00 | |
| 1/22/2016 | Susan M. Kanaya | CFO | Sell | 25,764 | $4.04 | $104,086.56 | |
| 1/20/2016 | Susan M. Kanaya | CFO | Sell | 14,971 | $4.10 | $61,381.10 | |
| 1/19/2016 | Susan M. Kanaya | CFO | Sell | 6,134 | $4.05 | $24,842.70 | |
| 1/15/2016 | Susan M. Kanaya | CFO | Sell | 300 | $4.00 | $1,200.00 | |
| 1/11/2016 | Geoffrey M Parker | Director | Buy | 20,000 | $4.63 | $92,600.00 | |
| 1/8/2016 | Susan M. Kanaya | CFO | Sell | 10,224 | $5.12 | $52,346.88 | |
| 1/6/2016 | Susan M. Kanaya | CFO | Sell | 47,607 | $6.98 | $332,296.86 | |
| 1/5/2016 | Susan M. Kanaya | CFO | Sell | 34,341 | $6.90 | $236,952.90 | |
| 1/4/2016 | Susan M. Kanaya | CFO | Sell | 10,490 | $7.38 | $77,416.20 | |
| 12/11/2015 | Geoffrey M Parker | Director | Buy | 20,000 | $7.25 | $145,000.00 | |
| 11/4/2015 | Value Fund L P Biotechnology | Insider | Sell | 360,000 | $7.00 | $2,520,000.00 | |
| 11/2/2015 | Value Fund L P Biotechnology | Insider | Sell | 50,000 | $6.97 | $348,500.00 | |
| 6/10/2015 | Bvf Partners L P/Il | Major Shareholder | Sell | 955,700 | $9.00 | $8,601,300.00 | |
| 5/22/2015 | Ira Klein | Director | Sell | 10,811 | $7.44 | $80,433.84 | |
| 4/1/2015 | Thomas J Schall | CEO | Sell | 24,267 | $7.50 | $182,002.50 | |
| 3/31/2015 | Thomas J Schall | CEO | Sell | 16,540 | $7.55 | $124,877.00 | |
| 3/30/2015 | Thomas J Schall | CEO | Sell | 1,200 | $7.51 | $9,012.00 | |
| 3/24/2015 | Thomas J Schall | CEO | Sell | 50,371 | $7.84 | $394,908.64 | |
| 3/19/2015 | Thomas J Schall | CEO | Sell | 18,146 | $8.34 | $151,337.64 | |
| 3/17/2015 | Thomas J Schall | CEO | Sell | 31,316 | $8.55 | $267,751.80 | |
| 3/9/2015 | Markus J Cappel | Treasurer | Sell | 34,125 | $7.81 | $266,516.25 | |
| 3/4/2015 | Markus J Cappel | Treasurer | Sell | 40,875 | $7.98 | $326,182.50 | |
| 3/3/2015 | Markus J Cappel | Treasurer | Sell | 5,943 | $7.81 | $46,414.83 | |
| 3/2/2015 | Markus J Cappel | Treasurer | Sell | 14,390 | $8.13 | $116,990.70 | |
| 11/18/2014 | Anne-Marie Duliege | EVP | Sell | 4,970 | $4.71 | $23,408.70 | |
| 5/1/2014 | Thomas J Schall | CEO | Sell | 27,726 | $5.59 | $154,988.34 | |
| 4/29/2014 | Thomas J Schall | CEO | Sell | 32,274 | $5.38 | $173,634.12 | |
| 4/22/2014 | Markus J Cappel | Treasurer | Sell | 20,962 | $8.17 | $171,259.54 | |
| 3/17/2014 | Thomas J Schall | CEO | Sell | 20,000 | $7.25 | $145,000.00 | |
| 12/6/2013 | Geoffrey M Parker | Director | Buy | 20,000 | $5.15 | $103,000.00 | |
| 12/5/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 189,800 | $5.01 | $950,898.00 | |
| 11/6/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 136,066 | $4.92 | $669,444.72 | |
| 11/1/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 336,225 | $4.99 | $1,677,762.75 | |
| 10/9/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 1,289,354 | $5.34 | $6,885,150.36 | |
| 10/3/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 109,425 | $5.49 | $600,743.25 | |
| 9/13/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 325,635 | $5.95 | $1,937,528.25 | |
| 9/13/2013 | Joseph M Feczko | Director | Buy | 10,000 | $6.03 | $60,300.00 | |
| 8/13/2013 | Markus J Cappel | Treasurer | Sell | 5,459 | $12.90 | $70,421.10 | |
| 8/7/2013 | Petrus Bekker | SVP | Sell | 5,000 | $13.26 | $66,300.00 | |
| 8/5/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.42 | $67,100.00 | |
| 8/1/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.82 | $86,375.00 | |
| 7/17/2013 | Markus J Cappel | Treasurer | Sell | 5,459 | $14.52 | $79,264.68 | |
| 7/17/2013 | Petrus Bekker | SVP | Sell | 10,000 | $14.54 | $145,400.00 | |
| 7/16/2013 | Thomas J Schall | CEO | Sell | 22,089 | $14.39 | $317,860.71 | |
| 7/3/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.43 | $67,150.00 | |
| 7/2/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.88 | $86,750.00 | |
| 6/28/2013 | Susan M Kanaya | CFO | Sell | 36,942 | $14.31 | $528,640.02 | |
| 6/27/2013 | Petrus Bekker | SVP | Sell | 5,000 | $14.00 | $70,000.00 | |
| 6/21/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.00 | $81,250.00 | |
| 6/18/2013 | Markus J Cappel | Treasurer | Sell | 1,783 | $12.47 | $22,234.01 | |
| 6/17/2013 | Petrus Bekker | SVP | Sell | 5,000 | $12.00 | $60,000.00 | |
| 6/3/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.32 | $66,600.00 | |
| 5/30/2013 | Susan M Kanaya | CFO | Sell | 12,770 | $14.28 | $182,355.60 | |
| 5/28/2013 | Markus J Cappel | Treasurer | Sell | 3,676 | $14.10 | $51,831.60 | |
| 5/24/2013 | Petrus Bekker | SVP | Sell | 4,800 | $14.00 | $67,200.00 | |
| 5/17/2013 | Petrus Bekker | SVP | Sell | 15,000 | $13.97 | $209,550.00 | |
| 5/15/2013 | Markus J Cappel | Treasurer | Sell | 15,668 | $14.08 | $220,605.44 | |
| 5/15/2013 | Roger C Lucas | Director | Sell | 5,000 | $14.11 | $70,550.00 | |
| 5/15/2013 | Thomas J Schall | CEO | Sell | 7,600 | $14.04 | $106,704.00 | |
| 4/11/2013 | Markus J Cappel | Treasurer | Sell | 1,500 | $14.10 | $21,150.00 | |
| 4/11/2013 | Petrus Bekker | SVP | Sell | 3,979 | $14.03 | $55,825.37 | |
| 4/11/2013 | Thomas J Schall | CEO | Sell | 2,529 | $14.02 | $35,456.58 | |
| 3/6/2013 | Petrus Bekker | SVP | Sell | 11,502 | $13.98 | $160,797.96 | |
| 3/6/2013 | Thomas J Schall | CEO | Sell | 5,541 | $14.01 | $77,629.41 | |
| 3/4/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.87 | $69,350.00 | |
| 2/26/2013 | Juan C Jaen | SVP | Sell | 22,500 | $12.23 | $275,175.00 | |
| 2/22/2013 | Thomas J Schall | CEO | Sell | 7,500 | $12.06 | $90,450.00 | |
| 2/6/2013 | Roger C Lucas | Director | Sell | 3,857 | $11.52 | $44,432.64 | |
| 2/4/2013 | Juan C Jaen | SVP | Sell | 3,875 | $11.69 | $45,298.75 | |
| 1/17/2013 | Markus J Cappel | Treasurer | Sell | 2,700 | $11.16 | $30,132.00 | |
| 11/6/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 40,000 | $12.00 | $480,000.00 | |
| 10/4/2012 | Roger C Lucas | Director | Sell | 1,893 | $11.47 | $21,712.71 | |
| 10/1/2012 | Susan M Kanaya | CFO | Sell | 3,971 | $11.89 | $47,215.19 | |
| 10/1/2012 | Thomas J Schall | CEO | Sell | 15,000 | $11.53 | $172,950.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ChemoCentryx (NASDAQ:CCXI)
Latest Headlines for ChemoCentryx (NASDAQ:CCXI)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Anticipate ChemoCentryx, Inc. (CCXI) to Announce -$0.19 EPS
www.americanbankingnews.com - June 22 at 4:24 PM |
 | ETFs with exposure to ChemoCentryx, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 6:00 PM |
| ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : June 8, 2017
finance.yahoo.com - June 8 at 5:11 PM |
| Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis (FSGS)
finance.yahoo.com - June 6 at 4:25 PM |
| Zacks: Brokerages Anticipate ChemoCentryx Inc (CCXI) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - May 29 at 12:28 PM |
 | ChemoCentryx to Present at Two Upcoming Investor Conferences
feeds.benzinga.com - May 24 at 9:01 AM |
| ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
finance.yahoo.com - May 23 at 12:53 PM |
| ChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : May 15, 2017
finance.yahoo.com - May 16 at 12:48 PM |
| ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : May 12, 2017
finance.yahoo.com - May 12 at 4:45 PM |
| Edited Transcript of CCXI earnings conference call or presentation 10-May-17 9:00pm GMT
finance.yahoo.com - May 11 at 9:50 PM |
| ChemoCentryx Inc (CCXI) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 6:35 PM |
 | ChemoCentryx's (CCXI) CEO Thomas Schall on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 2:37 AM |
| ChemoCentryx reports 1Q loss
finance.yahoo.com - May 10 at 9:37 PM |
| Investor Network: Chemocentryx, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 4:23 PM |
| ChemoCentryx Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 4:23 PM |
| Brokerages Anticipate ChemoCentryx Inc (CCXI) to Post -$0.21 Earnings Per Share
www.americanbankingnews.com - May 9 at 12:58 AM |
| -$0.21 EPS Expected for ChemoCentryx Inc (CCXI) This Quarter
www.americanbankingnews.com - May 4 at 1:32 AM |
| ChemoCentryx Inc (CCXI) Director Sells $29,240.00 in Stock
www.americanbankingnews.com - May 4 at 1:27 AM |
| Somewhat Favorable News Coverage Extremely Likely to Impact ChemoCentryx (CCXI) Share Price
www.americanbankingnews.com - April 30 at 2:42 PM |
| ChemoCentryx (CCXI) Getting Somewhat Negative Press Coverage, Analysis Shows
www.americanbankingnews.com - April 27 at 5:38 PM |
| ChemoCentryx (CCXI) Earning Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - April 15 at 11:21 AM |
| ChemoCentryx Inc (CCXI) Expected to Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - April 12 at 8:22 PM |
| Short Interest in ChemoCentryx Inc (CCXI) Drops By 1.3%
www.americanbankingnews.com - April 8 at 7:08 AM |
| ChemoCentryx Inc (CCXI) Coverage Initiated by Analysts at JMP Securities
www.americanbankingnews.com - March 26 at 1:42 PM |
| ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
finance.yahoo.com - March 22 at 3:59 PM |
| 8:31 am ChemoCentryx confirms that the FDA granted orphan drug designation for avacopan in the treatment of patients with C3 glomerulopathy
finance.yahoo.com - March 22 at 3:59 PM |
| Zacks Investment Research Downgrades ChemoCentryx Inc (CCXI) to Hold
www.americanbankingnews.com - March 20 at 5:37 PM |
 | ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 14 at 9:06 PM |
| CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
us.rd.yahoo.com - March 14 at 9:06 PM |
| Zacks Investment Research Upgrades ChemoCentryx Inc (CCXI) to “Buy”
www.americanbankingnews.com - March 13 at 8:23 AM |
| CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 2 at 9:28 PM |
| ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017
finance.yahoo.com - March 1 at 10:40 AM |
| ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 8:35 AM |
| Coverage initiated on ChemoCentryx by JMP Securities
finance.yahoo.com - February 22 at 12:13 PM |
 | Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases
globenewswire.com - February 14 at 2:53 AM |
 | ChemoCentryx (CCXI) Announces Presentation of Data from ... - StreetInsider.com
www.streetinsider.com - January 21 at 9:16 PM |
 | ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq ... - Nasdaq
www.nasdaq.com - January 21 at 9:16 PM |
| ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor
www.nasdaq.com - January 20 at 10:20 PM |
| ChemoCentryx (CCXI) Announces Presentation of Data from Ongoing Phase Ib Trial of CCR2 Inhibitor CCX872 at ASCO
www.streetinsider.com - January 20 at 5:20 PM |
| ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco
us.rd.yahoo.com - January 20 at 5:20 PM |
| ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer
us.rd.yahoo.com - January 20 at 5:20 PM |
| 3:34 pm ChemoCentryx presents from a continuing open-label, single-arm Phase Ib clinical trial of CCX872 at ASCO 2017; plans to further investigate CCX872 in combination with a checkpoint inhibitor.
us.rd.yahoo.com - January 20 at 5:20 PM |
| ChemoCentryx (CCXI) Offers Update, Development Strategy
www.streetinsider.com - January 9 at 5:21 PM |
| ChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare Renal Diseases
finance.yahoo.com - January 9 at 5:20 PM |
| ChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 5:13 PM |
ChemoCentryx (CCXI) Chart for Tuesday, June, 27, 2017
